Wordt geladen...
Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
BACKGROUND: Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage paye...
Bewaard in:
| Gepubliceerd in: | J Am Heart Assoc |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4889192/ https://ncbi.nlm.nih.gov/pubmed/27153871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003221 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|